Replies to post #279599 on Avid Bioservices Inc (CDMO)

[biopharm]

...and we haven't heard boo about the number of patients in the "control group" that left for newer therapies when the data was presented. Why is that?

we haven't heard much boo about the sabotage attempts against Peregrine Pharmaceuticals either. Oh well, maybe part of the closed to the public sealed records mentions something by the Judge that says certain things can't be talked about or discussed by either party.

I guess all that matters is PS Targeting must only be FDA approved for a single condition FIRST and then more steps forward will take place.

Anyhow, it is all about BIOMARKERS. Plain and simple.

Lets see how Peregrine management has advanced BIOMARKERS in the month of December, but my guess is you already know PS Targeting biomarkers are being advanced.

[itsabouttime]

This was my immediate conclusion back in February. Ironically this could provide more validation in the trail. In spite of control arm issue Bio markers are relevant.







..and we haven't heard boo about the number of patients in the "control group" that left for newer therapies when the data was presented. Why is that?

I find it almost impossible that the control group just happened to have an incredible outcome without such a variable added to the equation.

They have to know the statistical facts related to that the control group of the phase 3...How many left and how did it positively impact their survival?